



# Mobility, Simplicity, and Reliability

Clear Direction.  From Diagnosis to Care.

**medRAD**® Salient  
Contrast Injection System

# Clear Direction: MEDRAD® Salient Dual With MP

The MEDRAD® Salient Dual System with multi-patient (MP) kit has been engineered to combine innovation and mobility in order to bring simplicity and reliability to your suite.



## Simplicity

- › Intuitive, icon-driven interface
- › Flexible workflow and software architecture
- › Single-action syringe loading
- › Easy installation
- › Battery operation for total mobility



## Reliability

- › Allows dependable, reproducible flow rates and pressures that can consistently deliver injection protocols
- › Provides a maximum pressure up to 300 psi and up to 10 mL/s
- › Enables accurate and repeatable contrast administration with power injection<sup>1-3</sup>





## Introducing the Salient MP Kit

Designed to streamline workflows and prevent patient-to-patient fluid path contamination, the MP Kit is a sustainable solution that offers:

- Easy setup: Provides the same ease of setup you have come to expect from MEDRAD® Salient
- Single-patient line: Prevents backflow and potential contamination
- Self-closing connections: Prevent dripping when disconnecting the patient line\*
- Sustainability: Salient MP 2.0 disposables (15 patients) produce only 0.760 kg of disposables/packaging waste compared to the 2.625 kg produced by the single-patient design over the same number of patients.\* Fewer syringes means less medical waste, which can help with disposal costs and reduce your carbon footprint.
- Multi-guard: Protects the fluid path from accidental touch



## Clinical Highlights of Saline Flush

### Reduce image artifacts

Using a saline flush helps minimise the streak artifacts that often occur as the superior vena cava empties into the right heart.<sup>4</sup>

### Improve and increase peak contrast enhancement

Using a saline flush pushes the contrast through the vascular system.<sup>4</sup>

### Controlled timing of contrast bolus

Using a saline flush creates a tight contrast bolus that enables precise timing of contrast in the vascular system, which is essential for multi-slice CT scanning.<sup>4</sup>

### Optimise contrast usage




Using a saline flush can prevent pooling of contrast in veins and the contrast connection line.<sup>4</sup>

\*Internal data on file

## Main Features and Benefits



### Dimensions



**“The main strengths and benefits of Salient are speed, ease of programming, and the wireless connection that allows us to move Salient around the CT room.”**

*Technologist, private practice  
(Colombia)*

**“Very cost-efficient consumables, the provider (Bayer MEDRAD®) pays attention to my needs, and the syringes are easy to load.”**

*Radiologist, private hospital  
(Mexico)*

**“Accurate injection rate, stable performance, convenient use, and easy to learn.”**

*Radiologist, public hospital  
(China)*

**“Simple and easy to use. It can be programmed for different types of scans.”**

*Radiologist, private hospital  
(India)*

Testimonials from Value Range Injector Needs: Final report Customer and Employee Surveys (2020)



## Versatility in Your Suite

The straightforward design of the Salient Dual offers flexibility for your daily operations.

- Cordless configuration:  
Creates a safer clinical environment
- Various positioning options:  
Accommodates a range of spaces
- Compact design:  
Enhances mobility  
Enables easy transport and storage
- Customised protocols:  
Creates customised protocols – up to six phases  
Saves up to 20 customised injection protocols





## Additional Tools for Enhanced Efficiency

Salient Dual can be further customised with the following accessories and features:

- Wireless control room monitor
- Protocol Assistant Tool (PAT)




Salient Workstation with the Protocol Assistant Tool (PAT)



## Bayer Is Your Partner

MEDRAD® injectors can support you in achieving diagnostic image quality for your patients and workflow efficiency in your CME procedures.

- The Protocol Assistant Tool (PAT) allows you to deliver customised contrast media protocols to your patients for many common CT examinations.
- Ultravist® works seamlessly with the Salient PAT software.
- PAT is populated with UV370 and 300 to help add efficiency and confidence to your workflow.
- Our Service and Applications Specialists provide quality service and solutions to meet your clinical, financial, and operational needs.
- To learn more about MEDRAD® Salient Dual and other Bayer products, please speak to your local representative.



## MEDRAD® Salient D Technical Specifications

### Functional

Maximum pressure	300 psi
Flow rate	0.1 to 10 mL/s
Maximum volume	190 mL
Multi-phase protocols	Up to six phases. Storage for 20 different named protocols
Manual fill rate	Up to 10 mL/s
Auto fill rate	Up to 10 mL/s

### Controls

Base	Line power, IEC inlet, on/off switch
Head	5.7" LCD touch screen, arm button, on/off soft switch
Infrared remote control	Inject start/stop

### Mechanical

Weight	26 kg (Dual)
Height	1315 mm
Floor area	500 mm x 500 mm
No. of wheels	4 casters, all individually locking

### Electrical

Line voltage	100 – 230 VAC
Line frequency	50/60 Hz
Battery operation	Dual batteries, sealed lead acid
Mains power operation	Simultaneous operation and battery charging
Contrast heat maintainer <i>(one (1) included)</i>	37°C +/- 4°C, 5W

### Ordering Details

PART NAME	PART NO.
Salient Single Injector With Remote Control Unit	DC009SW
Salient Dual Injector With Remote Control Unit	DC009DW
Connector Tubing for Dual <i>(box of 50)</i>	ZY5152
Connector Tubing Single <i>(box of 50)</i>	ZY5151
Syringe With Fill Spike <i>(box of 50)</i>	ZY6323
Syringe With Fill Spike, Single LPCT <i>(box of 50)</i>	ZY6324
Syringe With Quick Fill Tube, Single LPCT <i>(box of 50)</i>	ZY6325
Single-Patient Line <i>(250 cm)</i>	SP1003
MP Syringe	MP1001
Transfer Set and Connector Tubing	MP1002

## References:

1. Endrikat J, Barbat R, Scarpa M, Jost G, Ned A. Accuracy and Repeatability of Automated Injector Versus Manual Administration of an MRI Contrast Agent – Results of a Laboratory Study. *Invest Radiol.* Jan 2018;53(1):1–5.
2. McDermott M, Kemper C, Barone W, Jost G, Endrikat J. Impact of CT Injector Technology and Contrast Media Viscosity on Vascular Enhancement: Evaluation in a Circulation Phantom. *Br J Radiol.* May 1 2020;93(1109):20190868.
3. Jost G, Endrikat J, Pietsch H. The Impact of Injector-Based Contrast Agent Administration on Bolus Shape and Magnetic Resonance Angiography Image Quality. *Magn Reson Insights.* 2017;10:1178623x17705894.
4. Auler MA, Heagy T, Aganovic L, Brothers R, Costello P, Schoepfet UJ. Saline chasing technique with dual-syringe injector systems for multi-detector row computed tomographic angiography: rationale, indications, and protocols. *Curr Probl Diagn Radiol.* 2006;35(1):1–11.

## PBS Information: This product is not listed on the PBS.

### ULTRAVIST® (iopromide)

**INDICATIONS:** ULTRAVIST is indicated for all angiographic and urographic examinations and for contrast enhancement in computerised tomography. ULTRAVIST 300 or 370 is indicated for use in contrast-enhanced mammography in adults to visualise known or suspected lesions of the breast as an adjunct to mammography (with or without ultrasound). ULTRAVIST 240 is additionally indicated for lumbar myelography in adults. **CONTRAINDICATIONS:** known hypersensitivity or previous reaction to iodinated contrast media or excipients, immediate repeat myelography. ULTRAVIST 300 and 370 are contraindicated for intrathecal use. **PRECAUTIONS:** anaphylactoid/hypersensitivity or other idiosyncratic reactions; pretesting/sensitivity testing is not recommended, evaluate potential risk of hypothyroidism in patients with known or suspected thyroid dysfunction, monitor thyroid function in neonates who have been exposed to ULTRAVIST; patients with CNS disorders, exercise caution in situations of reduced seizure threshold; patients with pronounced states of excitement, anxiety and pain; patients with significant cardiac disease or severe coronary artery disease; thromboembolic events; patients with severely impaired renal function, combined renal and hepatic disease, combined renal and cardiac disease, anuria or when large doses are administered; ensure adequate hydration status before i.v. or i.t. administration to minimise PC-AKI and especially in renally impaired patients; patients with known or suspected pheochromocytoma; intravascular use in patients with autoimmune disorders, myasthenia gravis, cerebral angiography or peripheral angiography; intrathecal use in patients with seizure history; not for use in thoracic, cervical or total columnar myelography, cerebral ventriculography or cisternography; paediatrics; pregnancy (Category B2); effects on diagnosis and treatment of thyroid disorders with thyrotropic radioisotopes; avoid driving or operating machinery for the first 24 h after administration. **INTERACTIONS WITH OTHER MEDICINES:** metformin; neuroleptics and antidepressants; beta-blockers; interleukin-2. **ADVERSE EFFECTS:** Common: dizziness, headache, dysgeusia, blurred/disturbed vision, chest pain/discomfort, hypertension, vasodilation, vomiting, nausea, pain, injection site reactions, feeling hot. Refer to full PI for a complete list. **DOSAGE AND ADMINISTRATION:** Dosage should be adapted to age, weight, clinical question, examination technique and region to be investigated. Can be used with single-use or multi-patient use injector system. Administration may be intravascular or intrathecal depending on clinical problem and region to be investigated. For intrathecal use in myelography, only ULTRAVIST 240 is recommended and allow at least 48 h before repeat examination. Refer to full PI for details. Based on PI dated 18 December 2023.

Please review the full Product Information before prescribing. Approved PI available at <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2020-PI-02293-1> or upon request from Bayer Australia Ltd, ABN 22 000 138 714, 875 Pacific Highway, Pymble NSW 2073, phone 1800 008 757.

® Registered trademark of the Bayer Group, Germany

Clear Direction. ➤ From Diagnosis to Care.

The patient data that appear in this document are fictitious protected health information (PHI) and/or actual PHI from which all personally identifiable information (PII) has been removed or otherwise anonymized. No personally identifiable information is shown.

Bayer, the Bayer Cross, MEDRAD Salient, MEDRAD, and Salient are trademarks owned by and/or registered to Bayer in the US and/or other countries. Other trademarks and company names mentioned herein are properties of their respective owners and are used herein solely for informational purposes. No relationship or endorsement should be inferred or implied.

© 2025 Bayer. This material may not be reproduced, displayed, modified, or distributed without the express prior written consent of Bayer.



### Radiology

Bayer Australia Ltd  
875 Pacific Highway  
Pymble NSW 2073  
Australia  
Phone: 1800 008 757  
ABN: 22 000 138 714



### Manufacturer

Imaxeon Pty Ltd  
Unit 1, 38 – 46 South Street  
Rydalmere, NSW 2116  
Australia  
Phone: 02 8845 4999  
Fax: 02 8845 4936  
Customer Service: 1800 633 723

### Australian Sponsor

Imaxeon Pty Ltd  
Unit 1, 38 – 46 South Street  
Rydalmere, NSW 2116  
Australia  
Phone: 02 8845 4999  
Fax: 02 8845 4936  
Customer Service: 1800 633 723

